Targeting epigenetic enzymes in core binding factor AML

靶向核心结合因子 AML 中的表观遗传酶

• 批准号: nhmrc : 1123445
• 负责人: Prof Miles Prince
• 金额: $ 37万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-epigenetic-enzymes-factor-aml/947170
• 关键词: Targeting; epigenetic; enzymes; core; binding

Acute myeloid leukemia (AML) is a devastating disease and there are ~900 new cases diagnosed annually in Australia. A subset of AML, called core binding factor (CBF) AML is more responsive to conventional chemotherapies than other AMLs however patients still relapse indicating a need for new therapies. We will use preclinical models of CBF AML to identify the proteins and pathways that these leukemias are “addicted” to in order to develop new treatment options for these patients.

急性髓性白血病（AML）是一种毁灭性的疾病，在澳大利亚每年诊断出约900例新病例。AML的一个子集，称为核心结合因子（CBF）AML，比其他AML对常规化疗更敏感，但患者仍然复发，表明需要新的治疗方法。我们将使用CBF AML的临床前模型来鉴定这些白血病“成瘾”的蛋白质和途径，以便为这些患者开发新的治疗方案。